Christopher Torrance
Oprichter bij PhoreMost Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Catherine Beech | M | 67 |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | 11 jaar |
Sunil Shah | M | 51 |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | 21 jaar |
Steven J. Harper | M | - |
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | 11 jaar |
Neil Torbett | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 7 jaar |
Ashok Venkitaraman | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 10 jaar |
Grahame McKenzie | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 10 jaar |
Charli Batley | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 9 jaar |
Jeffrey James Roix | M | 44 |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | 8 jaar |
Prashanth Shah | M | 53 |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
Hazel Jones | M | - |
Enhanc3D Genomics Ltd.
Enhanc3D Genomics Ltd. BiotechnologyHealth Technology Enhanc3D Genomics is a private functional genomics company based in Cambridge, UK. Enhanc3D Genomics is developing a technology to unlock the full potential of the three-dimensional organization of the human genome. The British company's focus is on the non-coding regions of the genome, aiming to identify disease-associated genetic interactions and revolutionize target and biomarker discovery. The company's unique approach has the potential to make precision medicine an everyday reality for patients. Enhanc3D Genomics Ltd. was founded by Mikhail Spivakov, Peter Fraser, and Stefan Schönfelder. The CEO is Hazel Jones. | - |
Jonathan Milner | M | 59 |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | 9 jaar |
Robert G. Boyle | M | - |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
John Kurek | M | - |
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | - |
Hermann Hauser | M | 76 |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | - |
Lucy Donaldson | M | - |
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | - |
Cengiz Tarhan | M | - |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
William Graham Richards | M | 85 |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
Mohammad Fazeli | M | 59 |
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | - |
Andy Morley | M | - |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | 11 jaar |
David Barrett | M | - |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
Chris Reid | M | - |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
Loic Lhuillier | M | - |
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | 8 jaar |
Andrew Naylor | M | - |
Exonate Ltd.
Exonate Ltd. Medical/Nursing ServicesHealth Services Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom. | - |
Nigel Pitchford | M | 55 |
o2h Ltd
o2h Ltd Investment ManagersFinance O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Lok Chung Chan | M | 73 |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | - |
Alastair Kilgour | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | - |
Jeff Roix | M | - |
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 27 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Christopher Torrance
- Persoonlijk netwerk